kcnl-3 Antibody

What is KCNN3 and why are antibodies against it valuable in neurological research?

KCNN3 (also known as KCa2.3 or SK3) is a member of the small-conductance calcium-activated potassium channel family. This channel is voltage insensitive and activated by intracellular Ca²⁺ in the submicromolar range . It features six transmembrane domains with intracellular N- and C-termini, structurally similar to voltage-dependent K⁺ channels despite its voltage insensitivity .

Antibodies against KCNN3 are invaluable research tools because these channels play crucial roles in:

• Controlling neuronal firing patterns and shaping synaptic transmission

• Regulating afterhyperpolarization (AHP) in neurons

• Calcium signaling pathways in various tissues

• Maintaining membrane potential in excitable cells

The dysregulation of SK3 channels has been implicated in several neurological disorders including epilepsy and Parkinson's disease, making these antibodies essential for understanding pathological mechanisms and identifying potential therapeutic targets .

What detection applications are KCNN3 antibodies validated for?

KCNN3 antibodies have been validated for multiple experimental applications, with specific recommendations varying by antibody type:

For Anti-KCNN3 (KCa2.3, SK3) (N-term) Antibody:

• Western blot analysis (1:200 dilution for rat brain membranes)

• Immunohistochemistry (1:100 for mouse and human uterine tissue)

• Immunofluorescence for detection in substantia nigra pars compacta

For KCNN3/SK3 Monoclonal Antibody:

• Immunofluorescence/Immunocytochemistry (1:50-1:200 dilution)

• ELISA applications

• Flow cytometry for human samples

For KCNN3 Rabbit Polyclonal Antibody:

• Western blot

• Immunohistochemical analysis in human, mouse, and rat samples

The selection of the appropriate antibody and application should be based on your specific experimental design and target tissue type.

How should KCNN3 antibodies be stored to maintain optimal reactivity?

Proper storage is critical for maintaining antibody function. Based on manufacturer recommendations:

• Store at -20°C for long-term preservation

• Avoid repeated freeze/thaw cycles which can degrade antibody performance

• KCNN3 antibodies are typically supplied in storage buffers containing:

  • PBS with 0.05% proclin300

  • 0.05% BSA

  • 50% glycerol at pH 7.3

  • Alternatively, 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol

When working with the antibody, aliquot into smaller volumes upon first thaw to minimize freeze/thaw cycles. Most manufacturers guarantee activity for at least one year when stored properly at -20°C .

What are the recommended dilution ranges for different applications?

Optimal dilution ranges vary by application and specific antibody formulation:

It is recommended to optimize dilutions for your specific tissue/cell type and experimental conditions. Begin with the manufacturer's suggested range and adjust as needed based on signal-to-noise ratio in your preliminary experiments.

How can researchers validate the specificity of anti-KCNN3 antibodies?

Antibody specificity validation is crucial for reliable experimental results. Recommended validation approaches include:

• Blocking peptide controls: Preincubate the antibody with its immunizing peptide before application. For example, Anti-KCNN3 (KCa2.3, SK3) (N-term) Antibody can be preincubated with KCNN3/KCa2.3 (N-term) Blocking Peptide (#BLP-PC025) to confirm specificity in Western blot analysis .

• Knockout/knockdown controls: Test the antibody in tissues/cells where KCNN3 expression has been genetically ablated or reduced.

• Heterologous expression systems: Use cells with confirmed KCNN3 expression, such as CHO-K1 cells expressing human SK3, which have been validated for antibody testing at 1:1000 dilution .

• Co-localization studies: Verify KCNN3 detection by co-staining with other established markers. For example, dopaminergic neuronal expression can be confirmed by co-staining with tyrosine hydroxylase in substantia nigra pars compacta .

• Multi-antibody verification: Use multiple antibodies targeting different epitopes of KCNN3 to confirm consistent staining patterns.

What are effective troubleshooting strategies for weak or non-specific signals?

When experiencing detection challenges with KCNN3 antibodies:

For weak signals:

• Increase antibody concentration within recommended range

• Extend primary antibody incubation time (overnight at 4°C)

• Optimize antigen retrieval methods for fixed tissues

• Use more sensitive detection systems (e.g., amplification steps)

• Ensure protein loading is sufficient (for Western blots)

For non-specific signals:

• Increase blocking stringency (longer blocking times, different blocking agents)

• Use more stringent washing steps (increased wash buffer volume and duration)

• Decrease antibody concentration

• Test different fixation protocols that better preserve epitope structure

• Use the specific blocking peptide to identify non-specific bands/staining

For membrane proteins like KCNN3:

• Optimize protein extraction methods to maintain membrane protein integrity

• Consider non-denaturing conditions for certain applications

• Use extraction buffers optimized for membrane proteins

How can KCNN3 antibodies be used to investigate channel distribution in neurological disorders?

KCNN3 antibodies provide valuable tools for examining alterations in channel distribution and expression in neurological conditions:

• Parkinson's disease research: Anti-KCNN3 antibodies can detect SK3 channels in dopaminergic neurons of the substantia nigra pars compacta, a region critically affected in Parkinson's disease . Immunohistochemical co-localization with tyrosine hydroxylase allows specific analysis of SK3 expression in these vulnerable neurons.

• Epilepsy studies: Given SK3's role in controlling neuronal excitability, antibodies can reveal expression changes in epileptic brain tissue compared to controls.

• Quantitative analysis approaches:

  • Immunoblotting for total protein expression changes

  • Immunohistochemistry/immunofluorescence for spatial distribution alterations

  • Subcellular fractionation combined with immunoblotting to assess membrane vs. cytoplasmic localization

  • Super-resolution microscopy with KCNN3 antibodies for nanoscale distribution analysis

• Single-cell analysis: Combining KCNN3 immunolabeling with electrophysiological recordings to correlate channel expression with functional properties in specific neuronal populations.

What methodological approaches optimize KCNN3 detection in co-localization studies?

For effective co-localization studies examining KCNN3 with other cellular components:

• Sequential immunostaining protocol:

  • Fix tissue/cells using 4% paraformaldehyde to preserve antigenicity

  • Perform antigen retrieval if necessary (tissue-dependent)

  • Block with appropriate serum (5-10% normal serum)

  • Apply first primary antibody (e.g., Anti-KCNN3) overnight at 4°C

  • Apply fluorophore-conjugated secondary antibody (2 hours, room temperature)

  • Repeat with second primary antibody of different host species

  • Use secondary antibody with non-overlapping emission spectrum

  • Counterstain nuclei with DAPI

• Confocal microscopy optimization:

  • Use sequential scanning to prevent bleed-through

  • Establish negative controls (secondary antibody only)

  • Include single-label controls for spectral unmixing

  • Acquire z-stacks for three-dimensional analysis of co-localization

• Validated co-localization examples:

  • KCNN3 with tyrosine hydroxylase in dopaminergic neurons

  • KCNN3 with specific membrane microdomains

• Quantitative analysis:

  • Calculate Pearson's correlation coefficient

  • Measure Manders' overlap coefficient

  • Perform intensity correlation analysis

  • Use specialized co-localization software for statistical validation

How can researchers quantitatively assess changes in KCNN3 expression across experimental conditions?

For rigorous quantitative analysis of KCNN3 expression:

• Western blot quantification:

  • Use validated Anti-KCNN3 antibodies at established dilutions (1:200-1:5000 depending on specific antibody)

  • Include loading controls (β-actin, GAPDH) for normalization

  • Analyze multiple biological replicates (minimum n=3)

  • Use densitometry software with linear detection range

  • Apply appropriate statistical tests for between-group comparisons

• Quantitative immunohistochemistry:

  • Standardize all tissue processing steps

  • Process all experimental groups simultaneously

  • Capture images with identical acquisition parameters

  • Analyze using threshold-based or machine learning approaches

  • Measure parameters such as:

    • Staining intensity (integrated optical density)

    • Puncta density and size

    • Area fraction of positive staining

    • Cell-type specific expression using co-localization

• Single-cell analysis techniques:

  • Flow cytometry with permeabilization for intracellular domains

  • Single-cell RT-PCR correlated with immunocytochemistry

  • Patch-clamp electrophysiology combined with post-hoc immunolabeling

• Molecular quantification:

  • qRT-PCR to correlate protein levels with mRNA expression

  • Protein-protein interaction assays (co-IP, proximity ligation)

What approaches can be used to study KCNN3 trafficking and membrane localization?

Understanding KCNN3 trafficking and localization requires specialized techniques:

• Subcellular fractionation combined with immunoblotting:

  • Separate membrane, cytosolic, and organelle fractions

  • Use Anti-KCNN3 antibodies for Western blot detection in each fraction

  • Compare distribution across experimental conditions

• Live-cell imaging approaches:

  • Epitope tagging of KCNN3 in conjunction with antibody detection

  • Correlation with membrane markers and trafficking proteins

  • Time-lapse imaging to follow channel movement

• Super-resolution microscopy techniques:

  • STORM or PALM imaging with Anti-KCNN3 antibodies

  • Dual-color imaging with membrane domain markers

  • Nanoscale distribution analysis relative to synaptic structures

• Biotinylation assays:

  • Surface biotinylation to isolate membrane-expressed channels

  • Internalization assays to measure endocytosis rates

  • Recycling assays to measure channel turnover at the membrane

  • Detection of isolated fractions using Anti-KCNN3 antibodies

• Correlative microscopy approaches:

  • Combining electron microscopy with immunogold labeling using Anti-KCNN3 antibodies

  • Contextualizing KCNN3 localization within ultrastructural features

How can KCNN3 antibodies contribute to drug discovery and therapeutic development?

KCNN3 antibodies serve as critical tools in the development of channel-targeted therapeutics:

• Target validation studies:

  • Confirmation of KCNN3 expression in disease-relevant tissues

  • Correlation of expression levels with disease severity

  • Identification of specific cell types expressing the channel

• High-throughput screening support:

  • Validation of cellular models used in drug screening

  • Confirmation of target engagement after compound treatment

  • Assessment of KCNN3 expression modulation by candidate compounds

• Mechanism of action studies:

  • Examination of drug effects on KCNN3 trafficking

  • Investigation of protein-protein interactions affecting channel function

  • Detection of post-translational modifications influenced by drug candidates

• Therapeutic antibody development:

  • Generation of function-modulating antibodies targeting extracellular domains

  • Validation of antibody specificity and affinity

  • Assessment of functional effects on channel properties

• Pharmacodynamic biomarker development:

  • Monitoring KCNN3 expression changes in response to treatment

  • Correlation with electrophysiological or behavioral outcomes

  • Development of companion diagnostics for targeted therapies

What are the key differences between monoclonal and polyclonal KCNN3 antibodies?

Understanding the distinctions between antibody types is crucial for experimental design:

The choice between monoclonal and polyclonal antibodies should be guided by your specific experimental needs, with monoclonals preferred for highly specific detection and polyclonals often better for sensitive detection of low-abundance targets.

What emerging techniques are enhancing KCNN3 research using antibody-based approaches?

The field of KCNN3 research is advancing with several innovative methodologies:

• Multiplexed imaging technologies:

  • Mass cytometry (CyTOF) with metal-conjugated KCNN3 antibodies

  • Multiplexed immunofluorescence for simultaneous detection of KCNN3 with multiple markers

  • Imaging mass spectrometry combined with antibody detection

• Single-molecule localization techniques:

  • Quantum dot-labeled antibodies for long-term tracking

  • STORM/PALM super-resolution microscopy with specialized secondary antibodies

  • Single-particle tracking of KCNN3 channels in live cells

• Functional antibody applications:

  • Development of conformation-specific antibodies recognizing open/closed channel states

  • Channel-modulating antibodies targeting regulatory domains

  • Intrabodies for live-cell visualization and manipulation

• Spatial multi-omics integration:

  • Correlation of KCNN3 protein expression with spatial transcriptomics

  • Integration with proteomics data for comprehensive channel complex analysis

  • Machine learning approaches to identify novel expression patterns across tissues

• In vivo applications:

  • Near-infrared fluorophore-conjugated antibodies for deep tissue imaging

  • PET imaging with radiolabeled antibody fragments

  • Antibody-based biosensors for real-time monitoring of channel expression

These emerging approaches are expanding the capabilities of KCNN3 antibodies beyond traditional applications, enabling more sophisticated investigations into channel function and regulation in physiological and pathological states.